GRAILGRAL
Recorded

GRAIL 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration45 minParticipants13

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, ladies and gentlemen, and welcome to the GRAIL third quarter 2026 earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that this conference call is being recorded. GRAIL Investor Relations, please begin.

RelationsCompany Representative

Thank you, and thank you all for joining us today. On the call are Josh Ofman, our Chief Executive Officer, Aaron Freidin, Chief Financial Officer, Sir Harpal Kumar, Chief Scientific Officer and President Global Clinical and Medical Affairs, and Andy Partridge, Chief Growth Officer. I will remind you that we will be making forward-looking statements based on current expectations. It is our intent that all statements other than statements of historical fact, including statements regarding our anticipated financial results and commercial activity, will be covered by the safe harbor provisions for forward-looking statements under the federal securities laws. Forward-looking statements are subject to risk and uncertainties. Actual events or results may differ materially from those projected or discussed. All forward-looking statements are based upon currently available information, and GRAIL assumes no obligation to update these statements.

RelationsCompany Representative

To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the document that GRAIL files with the Securities and Exchange Commission, including the risk factors section in GRAIL's most recent annual report on Form 10-K and the quarterly report on Form 10-Q we plan to file for the third quarter of 2026. This call will also include a discussion of GAAP results and certain non-GAAP financial measures, including adjusted gross profit, adjusted gross margin, and adjusted EBITDA, which exclude certain specified items. Our non-GAAP financial measures are intended to supplement your understanding of GRAIL's financials. Reconciliations of the non-GAAP measures to most directly comparable GAAP financial measures are available in the press release issued today, which is available on our website. With that, we turn to Josh.

Joshua OfmanCEO

Thank you. Good afternoon, everyone, and thank you for joining us to review results for the third quarter of 2026 and to discuss recent business updates. GRAIL achieved multiple significant milestones this quarter, including a favorable vote for approval from the FDA's advisory committee and the publication of NHS-Galleri and PATHFINDER 2 results in The New England Journal of Medicine and Nature Medicine. These important clinical and regulatory milestones position us very well as we continue to progress towards future potential regulatory approval and reimbursement. As you know, we submitted our pre-market approval application for Galleri to the FDA in January of this year, and on September 23, the FDA convened an expert advisory committee to consider the safety, effectiveness, and overall benefit-risk profile of Galleri for screening for the early detection of multiple types of cancer in adults age 50 years and older.

Joshua OfmanCEO

Galleri is the first multi-cancer early detection test to undergo FDA review through the PMA pathway, and we were very pleased with the positive vote. The advisory committee discussion highlighted the high evidence bar that GRAIL has set for the entire field of multi-cancer detection tests. We are engaged in interactive communications with the FDA since the advisory committee, and we expect to receive a final decision by early Q1 of 2027. Galleri is supported by a broad evidence base demonstrating its ability to detect cancer signals across over 140 cancer types and subtypes, with a very low false positive rate, and accurately identify cancer signal origin for those positive signals to support an efficient and directed workup. Based on what has now been demonstrated, we believe that adding Galleri to recommended single cancer screens can dramatically improve the effectiveness and the efficiency of national screening programs around the globe.

Joshua OfmanCEO

This is best exemplified by a clear finding from the NHS-Galleri randomized controlled trial. When Galleri was added to standard of care, more than four times more cancers were identified overall, and Galleri found more stage 1 and 2 cancers than the entire U.K.'s national screening program found all cancers across all stages. This is remarkable and gives confidence that we can help improve how we screen for cancer and find cancers early before symptoms when there are opportunities for cure. We are very proud of our clinical evidence base, which we believe speaks for itself, and we continue to present and publish our studies in world-leading forums. In September, results from our two largest prospective studies, NHS-Galleri and PATHFINDER 2, were published in The New England Journal of Medicine and Nature Medicine.

Joshua OfmanCEO

These publications build on the results we presented at ASCO earlier this year and demonstrate the many clinically meaningful benefits of Galleri. Across these studies, Galleri has detected over 140 distinct types and subtypes of cancer. We believe the results of the NHS-Galleri trial demonstrated compelling clinical utility. Though we did not observe a combined reduction in stage 3 and 4 cancers, GRAIL demonstrated the ability to generate a stage shift in cancer detection, producing a clinically meaningful reduction in stage 4 diagnoses. This is a historic achievement. Performance metrics such as PPV and safety in both the PATHFINDER 2 and NHS-Galleri study were strong and consistent across populations and studies. Together, these studies demonstrate the consistency of GRAIL's performance across two very large screening populations and two unique healthcare systems.

Joshua OfmanCEO

We believe the results provide strong evidence that adding Galleri to standard of care screening can substantially increase the number of cancers identified through screening while maintaining a favorable safety profile. The clinical utility metric of overall cancer detection is compelling, a 4 to 6.5-fold increase in cancer detection through screening, almost half of which are early stage 1 and 2 cancers, and a 20% reduction in the incidence of stage 4 disease in a pre-specified group of 12 deadly cancers, a 25% reduction in the emergency room diagnosis of cancer, and of GRAIL-detected cancers at stage 1 through three, more than 80% were treated with curative intent.

Joshua OfmanCEO

As we await an FDA decision, we are focused on making investments that help us to clearly differentiate GRAIL and reduce much of the noise and confusion that exists in the marketplace, and we are also preparing for engagement with commercial payers and CMS. Turning to commercial performance in 2026, we continued to gain traction and see encouraging levels of volume growth. Test volumes increased 24% in Q3 as compared to the prior year, and to date, we have completed more than 174,000 tests in the first three quarters of the year, an increase of 36% from the prior year. In June, we expanded our provider sales force, and we continue to ramp new personnel toward full productivity as we come out of the summer slowdown. We are also expanding access across provider, health system, employer, and digital channels through new and existing partnerships.

Joshua OfmanCEO

We rolled out our first Epic integration at the end of Q3, and we expect several more integrations through the end of the year. Q3 has typically been a relatively slow quarter, and the effect was compounded this year by the impact in the marketplace related to negative headlines about the NHS-Galleri results, which continued during and after ASCO. Combined with a very active competitive marketplace, this tempered growth in Q3. We expect a potential FDA approval would enable us to clarify the strength of GRAIL's safety and performance data and reinforce that GRAIL is the only FDA-approved MCED test, helping to create a bifurcated market with clear differentiation of GRAIL. After potential FDA approval, GRAIL will stand in a category all on its own. Right now, there is confusion in the marketplace about which MCEDs may be FDA approved.

Joshua OfmanCEO

At this time, all MCEDs are lab-developed tests, but there is a perception that these tests are similar, but of course, they are far from the same. Comparing test performance from small case-controlled studies to large interventional studies in the screening population is simply not scientifically appropriate, and we believe that it is important for the benefits and harms to be understood through interventional studies in the screening population. On the heels of a positive FDA advisory committee and in anticipation of a potential FDA approval, we have started pulling forward our commercial investment, including the sales force expansion, launching our price promotion early, and increased investing in direct-to-consumer advertising. We expect to further increase investment in brand awareness and competitive differentiation going forward as we reshape the market. If we obtain FDA approval, we will clearly differentiate GRAIL as a robust, well-validated FDA-approved test.

Joshua OfmanCEO

Overall, GRAIL has had a very busy quarter. We achieved an important regulatory milestone with the favorable FDA advisory committee vote, we strengthened GRAIL's evidence base through publication of our two landmark clinical studies, and we continued to drive commercial penetration and build the foundation for broad market access. We are well-positioned for continued growth as the clear leader in the MCED field, and we are looking forward to a near-term FDA decision. We are preparing to drive growth acceleration if we receive approval. We believe this milestone will help support advancing engagements with health systems, self-insured employers, payers, and guideline developers, as well as supporting greater conviction among providers and consumers. I'll now hand it over to Aaron for a review of our third quarter financials.

Aaron FreidinCFO

Thanks, Josh, and good afternoon, everyone. In Q3, we reported revenue of $37.5 million, up $1.3 million or 4% as compared to the third quarter of 2025. Total revenue for the third quarter consisted of $37.3 million of screening revenue and $0.2 million of development services revenue. Screening revenue was up 14% as compared with the third quarter of 2025, with test volumes of more than 56,000, an increase of 24% over the third quarter of 2025. Test volumes were moderately lower in Q3 compared to Q2, which is consistent with the seasonality pattern we've observed in Galleri sales since launch, with quarters one and three being relatively soft compared to quarters two and four, and additionally reflects the headwinds we've seen in this market. Overall, Galleri test volume grew 36% over the first nine months of 2026 compared with the same period the prior year.

Aaron FreidinCFO

In parallel, ASPs have come down, resulting in a 24% growth in revenue over the first nine months compared to the year prior. In preparation for an FDA decision and in response to softer growth in the first two months of the quarter, we initiated a pricing promotion in September. We know that price is a significant barrier in the self-pay market, and we expect, as we have seen in the past, that the promotional pricing will generate additional demand. As a result of pricing promotion, our Q3 ASP has come down to approximately $660 a test. We are intentionally prioritizing growth and market penetration over margin optimization in the short term to drive market momentum as we approach an FDA decision and other meaningful milestones. We believe expanding volume grows the experience of providers and patients, provides more opportunity for repeat testing, and drives down COGS over time.

Aaron FreidinCFO

We have long expected that price levels will come down over time to support broad-scale adoption as the MCED legislation ties the price to Cologuard, and the current pricing promotion will provide us with important data to set pricing strategy for the interim period before broad reimbursement. As a reminder, the legacy Illumina royalty, which has been suspended, will resume in late December 2026. In 2026, we have been including in our quarterly filings the calculation for the royalty that would have been paid had it not been suspended. For example, in Q3, we would have paid $2.6 million. In the first quarter of 2027, gross margin will be fully impacted by this royalty for the first time since we spun out as a public company. However, as you know, with our highly automated lab, our gross margins will improve as volumes grow.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day